Enlivex Therapeutics Ltd.
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
ENLV | TA
Overview
Corporate Details
- ISIN(s):
- IL0011319527
- LEI:
- Country:
- Israel
- Address:
- Weizmann Science Park, 14 Einstein St., 7403618 Ness Ziona
- Website:
- https://enlivex.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Enlivex Therapeutics Ltd. is a clinical-stage biopharmaceutical company developing macrophage reprogramming immunotherapies. Its lead product candidate, Allocetra™, is a universal, off-the-shelf cell therapy platform designed to restore immune system balance. The company is evaluating Allocetra™ in clinical trials for the treatment of a range of indications, including acute inflammatory conditions like sepsis and chronic inflammatory diseases such as osteoarthritis. The therapy is designed for flexible administration and has demonstrated a favorable safety profile in patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-18 16:14 |
Regulatory News Service
Results of a meeting held on November 7, 2025
|
Hebrew (modern) | 127.9 KB | ||
| 2025-11-18 16:14 |
Foreign Filer Report
Results of a meeting held on November 7, 2025
|
English | 36.3 KB | ||
| 2025-11-15 00:39 |
Regulatory News Service
Report of Periodic or Interim Report
|
Hebrew (modern) | 325.9 KB | ||
| 2025-11-15 00:39 |
Foreign Filer Report
Report of Periodic or Interim Report
|
English | 36.6 KB | ||
| 2025-11-11 10:09 |
Proxy Solicitation & Information Statement
Immediate Report of Meeting
|
English | 161.3 KB | ||
| 2025-11-11 10:09 |
Pre-Annual General Meeting Information
Immediate Report of Meeting
|
English | 130.4 KB | ||
| 2025-11-11 10:04 |
Foreign Filer Report
Annual Meeting will be reconvened on Monday, November 17, 2025, beginning at 7:…
|
English | 130.2 KB | ||
| 2025-11-11 10:04 |
Foreign Filer Report
Annual Meeting will be reconvened on Monday, November 17, 2025, beginning at 7:…
|
English | 36.3 KB | ||
| 2025-09-26 01:42 |
Proxy Solicitation & Information Statement
Immediate Report of Meeting
|
English | 161.3 KB | ||
| 2025-09-26 01:42 |
Foreign Filer Report
Immediate Report of Meeting
|
English | 198.6 KB | ||
| 2025-09-26 01:42 |
Pre-Annual General Meeting Information
Immediate Report of Meeting
|
English | 130.5 KB | ||
| 2025-09-11 17:22 |
Foreign Filer Report
Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following…
|
English | 194.2 KB | ||
| 2025-09-11 17:22 |
Foreign Filer Report
Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following…
|
English | 36.3 KB | ||
| 2025-09-09 17:16 |
Foreign Filer Report
Enlivex Announces Issuance of New Patent Application Covering the Use of Alloce…
|
English | 228.7 KB | ||
| 2025-09-09 17:16 |
Foreign Filer Report
Enlivex Announces Issuance of New Patent Application Covering the Use of Alloce…
|
English | 36.3 KB |
Automate Your Workflow. Get a real-time feed of all Enlivex Therapeutics Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Enlivex Therapeutics Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Enlivex Therapeutics Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
